Identifying novel targets for antibody-drug conjugates in sarcomas using RNA sequencing
Authors
- 1 BostonGene, Corporation, Waltham, MA, USA
- 2 Massachusetts General Hospital, Boston, MA, USA
- 3 The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 4 Memorial Sloan Kettering Cancer Center, New York, USA
- 5 Sarcoma Oncology Center, Santa Monica, CA, USA
Abstract
Antibody-drug conjugates (ADCs) targeting precise surface antigens are pivotal to advancing targeted cancer therapies. Here, we analyzed transcriptomic data from sarcoma samples to identify novel cell surface protein candidates for designing new and highly specific ADCs with potential minimal side effects.
Methods:
We processed 826 FFPE samples (soft tissue or bone tumors) by whole-exome and RNA sequencing as described previously [1]. To study target expression in carcinomas and normal tissues, we utilized TCGA datasets and normal samples from the Adult GTEx project dataset [2], retrospectively. Information on 82 ADC targets and relevant clinical trials (until January 2024) was extracted from ClinicalTrials.gov [3,4]. We employed the Mann-Whitney U-test (with false discovery rate correction) to compare ADC target expression in a given sarcoma diagnosis against all others, highlighting genes highly expressed (≥4 log2 transcripts per million (TPM)) in sarcomas but lowly expressed (<2 log2 TPM) in normal tissues. Additionally, we examined the expression profiles of tertiary lymphoid structure (TLS)- and immune checkpoint (IC)-associated genes as previously described [5].
Results:
Heatmap of RNA expression in Figure 1 depicts 20 ADC targets currently prioritized for clinical trial investigation. Table 1 lists the top 10 potential ADC targets based on expression level. Table 2 lists potential ADC targets with low expression in normal tissues but high expression in certain sarcomas, along with highly expressed TLS- and IC-associated genes. Combined expression of ADC targets, TLS markers, IC molecules indicates complex immune landscapes among different sarcoma subtypes that may benefit from combination therapies involving ADCs. Interestingly, only 4 genes from both Tables 1 and 2 overlap with the 20 prioritized targets in Figure 1. Therefore, the expression profiles we uncovered also unveil new potential ADC targets that warrant further investigation.
Conclusions:
This study uncovered the expression landscape of potential ADC targets in sarcomas, particularly those lowly expressed in normal tissues. Expression profiles of TLS and IC gene signatures combined with ADC target expression characterize the immune landscape of sarcomas and can guide the development of immunotherapy approaches. Existing ADC clinical trials preclude many of these genes, underscoring the need for new trials that investigate these candidates. Our findings support the advancement of precision oncology in sarcoma therapies that prioritize safety and efficacy to improve patient outcomes.
Latest publications
